F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan

Endocrine Research

Volumn 29, Issue 2, 2003, Pages 169-175

  Hung, Min Chang ^a   Wu, Hurng Sheng ^a   Kao, Chia Hung ^b   Chen, Wen Kang ^c   Changlai, Sheng Pin ^c  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

F18 fluorodeoxyglucose positron emission tomography; Papillary thyroid carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; HYPERMETABOLISM; LUNG METASTASIS; MALE; METASTASIS; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOISOTOPE THERAPY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING; X RAY;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 0038683747     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1081/ERC-120022297     Document Type: Article

References (20)

1. Collins SL. Thyroid cancer: controversies and etiopathogenesis. In: Falk SA, ed. Thyroid Disease. Endocrinology, Surgery, Nuclear Medicine, and Radiotherapy. 2nd ed. Philadelphia: Lippincott-Raven, 1997:495-564.
2. Mazzaferri EL. Diagnosis and management of papillary and follicular thyroid carcinomas. In: Surks MI, ed. Thyroid Diseases. Philadelphia: Blackwell Science, 1999:67-80.
3. Ronga G, Fiorentino A, Paserio E, Signore A, Todino V, Tummarello MA, Filesi, Baschieri I. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med 1990; 31:1766-1771.
4. Lubin E, Mechlis-Frisch S, Zatz S, Shimoni A, Segal K, Avraham A, Levy R, Feinmesser R. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994; 35:257-262.
5. Roelants V, De Nayer P, Bouckaert A, Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24:722-727.
6. Filesi M, Signore A, Ventroni G, Melacrinis FF, Ronga G. Role of initial iodine-131 whole body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 1998; 39:1542-1546.
7. Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin North Am 1996; 25:93-113.
8. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985; 60:376-380.
9. Shen YY, Kao A, Yen RF. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 2002; 9:321-325.
10. Yen RF, Sun SS, Shen YY, Changlai SP, Kao A. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001; 21:3691-3694.
11. Sun SS, Chen TC, Yen RF, Shen YY, Changlai SP, Kao A. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 2001; 21:2957-2961.
12. Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 2001; 21:1375-1378.
13. Changlai SP, Tsai SC, Chou MC, Ho YJ, Kao CH. Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep 2001; 8:337-339.
14. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF, ChangLai SP, Chieng PU. Comparison of 18-fluoro-2-deoxyglucose positron emission tomography and computed tomography in detection of cervical lymph node metastases of nasopharyngeal carcinoma. Ann Oto Rhinol Laryn 2000; 109:1130-1134.
15. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000; 20:2189-2192.
16. Kao CH, ChangLai SP, Chieng PU, Yen RF, Yen TC. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 1998; 16:3550-3555.
17. Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, Palmedo H, Ruhlmann J, Kozak B, Biersack HJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23:312-319.
18. 131I wholebody scan. J Nucl Med 1999; 40:986-992.
19. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhfle H, Müller-Schanenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37:1468-1472.
20. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorin-18 fluorodeoxyglucose. J Nucl Med 1987; 28:910-914.